Docetaxel-associated palmar-plantar erythrodysesthesia is rarely reported in literature, particularly when used in the treatment of sarcomas. Here, we report a case of docetaxel-related palmar-plantar erythrodysesthesia in a 28-year-old male with recurrent Ewing sarcoma. Although palmar-plantar erythrodysesthesia has been seen in the literature for 30 years, there has still been little progress in understanding and appropriately addressing this adverse effect. This case report and literature review illustrates an infrequently documented adverse skin reaction and discusses the etiology, presentation, and available treatment options for palmar-plantar erythrodysesthesia.

Conflict of interest: EAB has been the recipient of grant funding to her institution from Merck, Takeda (Shire), and Hologic for clinical trials related to cytomegalovirus; payments for Data Safety Monitoring Board participation from Amplyx (for a trial related to BK virus treatment) and the NIH; support for attending meetings from the American Society of Transplantation and the University of Colorado; payments for editorial board participation from UptoDate and the American Society of Transplantation; and has served on the board of the American Society of Transplantation and as a committee chair for the American Society of Transplantation. IF has received grant funding through his institution from Moderna, Janssen, Sanofi, and Pfizer for clinical trials and payment for participation in advisory boards from Gilead and ViiV. BMH, KC, CMB, and SEC are employees of NanoString Technologies and all are stockholders in this company. EOH has received grants through her institution from the National Cancer Institute, Tmunity Therapeutics, Blueprint Medicines, and Abbvie. She has received consulting fees from the American Board of Internal Medicine and has participated in the Data Safety Monitoring Boards for Pharmessentia, Inc. and Blueprint Medicines. JAF and CHJ receive research funding supported in part by a grant from the Parker Institute for Cancer Immunotherapy.

No abstract

No abstract

No abstract